Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp cut its holdings in Humana Inc (NYSE:HUM) by 8.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,500 shares of the insurance provider’s stock after selling 5,400 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Humana were worth $18,602,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also bought and sold shares of the company. Synovus Financial Corp purchased a new position in shares of Humana in the 1st quarter worth approximately $100,000. Sun Life Financial INC boosted its stake in shares of Humana by 120.7% in the 2nd quarter. Sun Life Financial INC now owns 373 shares of the insurance provider’s stock worth $111,000 after buying an additional 204 shares during the last quarter. Stratos Wealth Partners LTD. boosted its stake in shares of Humana by 448.7% in the 1st quarter. Stratos Wealth Partners LTD. now owns 417 shares of the insurance provider’s stock worth $112,000 after buying an additional 341 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Humana in the 1st quarter worth approximately $113,000. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of Humana by 2,984.6% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock worth $119,000 after buying an additional 388 shares during the last quarter. 92.99% of the stock is owned by hedge funds and other institutional investors.
In related news, CEO Bruce D. Broussard sold 18,000 shares of the company’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $328.66, for a total value of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares in the company, valued at $23,362,796.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the completion of the transaction, the insider now owns 14,289 shares of the company’s stock, valued at $4,715,370. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,284 shares of company stock worth $13,147,715. Insiders own 0.60% of the company’s stock.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Humana from a “buy” rating to a “hold” rating in a research note on Friday. ValuEngine upgraded Humana from a “hold” rating to a “buy” rating in a research note on Wednesday, July 4th. BMO Capital Markets upped their price objective on Humana from $328.00 to $355.00 and gave the company an “outperform” rating in a research note on Monday, June 25th. Cowen began coverage on Humana in a research note on Monday, September 17th. They issued a “market perform” rating and a $372.00 price objective on the stock. Finally, SunTrust Banks reiterated a “hold” rating and issued a $350.00 price objective on shares of Humana in a research note on Thursday, August 2nd. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $339.79.
Shares of Humana stock traded down $0.08 during trading on Friday, hitting $331.14. The stock had a trading volume of 398,847 shares, compared to its average volume of 758,391. The stock has a market cap of $46.64 billion, a P/E ratio of 28.28, a PEG ratio of 1.69 and a beta of 0.97. Humana Inc has a 12 month low of $231.90 and a 12 month high of $341.30. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.43.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.17. The firm had revenue of $14.26 billion for the quarter, compared to analysts’ expectations of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same quarter in the prior year, the firm posted $3.49 earnings per share. Sell-side analysts predict that Humana Inc will post 14.18 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, September 28th will be issued a $0.50 dividend. The ex-dividend date is Thursday, September 27th. This represents a $2.00 annualized dividend and a dividend yield of 0.60%. Humana’s payout ratio is currently 17.08%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Read More: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.